Evidence map›Paper›PMID 40184226›Full record

SynthesisFuture oncology (London, England)2025

Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis.

Philippe Barthélémy, Mihaela G Musat, Hoora Moradian, Mairead Kearney

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Philippe BarthélémyMedical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
Mihaela G MusatCytel, Waltham, MA, USA.ORCID 0000-0001-5575-3809
Hoora MoradianCytel, Waltham, MA, USA.
Mairead KearneyMerck Healthcare KGaA, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis systematic literature review summarizes the real-world effectiveness, safety, and tolerability of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC). MATERIALS &

methodsDatabase searches (MEDLINE, Embase, Cochrane) and manual gray literature searches of real-world studies published from 01/01/2020-31/01/2024 were performed. Pooled 12-month overall survival (OS) and progression-free survival (PFS) rates were synthesized by meta-analysis.

resultsAcross 45 unique studies including >2,600 patients, median OS and PFS were 21.3 and 7.0 months, respectively. In the meta-analysis, 12-month OS and PFS rates (95% CI) from avelumab 1LM start were 69% (65-73%) and 39% (35-44%), respectively.

conclusionThis study supports the established clinical benefit of avelumab 1LM across a broad range of patients with la/mUC in routine practice.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Transitional CellUrologic NeoplasmsHumansMaintenance ChemotherapyProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalavelumabavelumabfirst-line maintenancelocally advanced or metastatic urothelial carcinomaReal-world evidencesystematic literature review

Identifiers

PMID40184226
PMCPMC11988210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.